Navigation Links
Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Date:5/12/2008

weeks for a total of 6 doses. All patients will have active RA while on methotrexate. The trial is expected to enroll 70 patients at multiple sites in Europe. The primary endpoint of the study is the ACR20 response, a composite endpoint that indicates a 20% improvement in RA signs and symptoms, at 12 weeks.

Medarex also announced that results from the MDX-1100 Phase 1 trials will be presented at the Digestive Disease Week (DDW) meeting, being held May 17 - 22, 2008 in San Diego. The following abstracts are expected to be the subject of presentations at the DDW 2008 conference:

-- "A Double-Blind, Placebo-Controlled, Dose-Escalation, Safety and

Pharmacokinetic Study of MDX-1100, a Fully Human Anti-CXCL10 Monoclonal

Antibody, in Healthy Subjects" (Abstract #T1145) - Poster presentation

on May 20, 2008 from 12:00 to 2:00 PM CDT.

-- "A Phase 1 Open-Label, Single-Dose, Dose-Escalation Study of MDX-1100,

a High-Affinity, Neutralizing, Fully Human IgG1k Anti-CXCL10 (IP10)

Monoclonal Antibody, in Ulcerative Colitis" (Abstract #704) - Oral

presentation on May 20, 2008 from 3:00 to 3:15 PM CDT.

-- "CXCL10 Expression and Biological Activities in Inflammatory Bowel

Disease" (Abstract #W1170) - Poster presentation on May 21, 2008 from

12:00 to 2:00 PM CDT.

These presentations support the development of MDX-1100 for the treatment of inflammatory diseases such as ulcerative colitis and rheumatoid arthritis.

About MDX-1100

MDX-1100 is a fully human antibody that targets CXCL10 (also known as IP-10), a chemokine expressed in association with multiple inflammatory disease indications such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.

About Ulcerative Colitis

Ulcerative colitis (UC) is a chronic inflammatory bowel disease of the colon and is characterized by inflammation and ulceration of the lining of the colon. Sy
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 2014  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... Dental Supply, Inc., a leading full-service provider of dental ... Schein,s entrance into Japan , the ... to 28 the number of countries in which the ...
(Date:10/17/2014)... 2014  Training market researchers to spot and ... in today,s highly competitive global marketplace. As resources ... effectively and efficiently produce high performing analysts, regardless ... Effective training programs can help these ... internal clients by developing analysts who can drive ...
(Date:10/17/2014)... 2014 ... the addition of the  "China Interventional Cardiovascular ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... China impacted by accelerated ... concept, dietary habit, way of working and ...
Breaking Medicine Technology:Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3
(Date:10/20/2014)... October 20, 2014 Allegheny General Hospital’s ... that enables physicians to repair a damaged mitral valve ... MitraClip system, developed by Abbott Vascular , ... progressive and life-threatening condition in which the heart’s mitral ... flow backward from the heart’s left ventricle into the ...
(Date:10/20/2014)... 20, 2014 hc1.com today announced ... cloud solution that enables healthcare organizations of all ... healthcare-specific customer relationship management (“CRM”) solution. , Designed ... needs of the healthcare industry, the hc1 Healthcare ... and patients by combining healthcare CRM, HIPAA-compliant collaboration, ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Sit and Slim II . , The FDA ... Sit and Slim II because it contains Sibutramine ... loss product on various websites and possibly in some retail ... safety reasons, can significantly increase blood pressure and/or pulse rate ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 National Teen ... Chapter of the American Academy of Pediatrics (Ohio AAP, ... (NHTSA) in encouraging parents of teen drivers to talk to ... the road. , Motor vehicle crashes are the leading cause ... teen drivers involved in fatal crashes, and 859 (42%) of ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher ... of his innovative True Form Tummy Tuck® ... and faculty at The University of Texas Medical ... once a medical student. Patronella, who is a founding ... surgery practices in Texas, The Aesthetic Center for ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... Iowa, Oct. 30 Barack Obama today,stepped ahead of ... most,critical areas of foreign policy, the effort to eradicate ... this area, he pledged to,increase spending on global HIV/AIDS ... same time increasing overall foreign assistance spending to,$50 billion ...
... radiotherapy to treat breast cancer may, in some cases, ... toxic radiation as does the standard six weeks of ... because the short treatment, known as partial breast irradiation, ... through multiple beams, these beams can pass through the ...
... Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ), a ... clinical-stage product candidates for central,nervous system disorders, today ... II clinical trial evaluating VSF-173 in a,clinical model ... examined the effects of VSF-173 on a model ...
... PharmAthene, Inc., a leading,biodefense company specializing in the ... biological terrorism,announced today that it is scheduled to ... 9th Annual Healthcare Conference on Tuesday, November 6, ... Company will be David P.,Wright, President and Chief ...
... vitamin D levels and the overall risk of dying ... 30 in the Journal of the National Cancer ... with a decreased risk of colorectal cancer death. , ... vitamin D can reduce cancer mortality by decreasing cancer ...
... (NASDAQ: ANPI , TSX: ANP), a global ... participate in the CIBC 18th Annual,Healthcare Conference, which ... New York City. Tom Bailey, Angiotech Chief ... a 30-minute break-out session on Monday, November,5, beginning ...
Cached Medicine News:Health News:Obama Pledges Major Expansion of AIDS and Global Poverty Programs 2Health News:Normal tissue not spared in new forms of breast cancer radiotherapy 2Health News:Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties 2Health News:Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties 3Health News:Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties 4Health News:Study finds no connection between vitamin D and overall cancer deaths 2
The Precedent establishes a new generation of revision hip stems....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Calcar replacement stems provide options for revision and trochanteric fractures. Revision hip surgery and trauma often require prosthetic designs that replace proximal medial calcar bone loss....
... materials contributes to successful outcomes for ... procedures and technique, the materials you ... your patients' outcomes, both short-term and ... Cross-Linked Polyethylene. MARATHON Polyethylene is the ...
Medicine Products: